Size controlled protein nanoemulsions for active targeting of folate receptor positive cells
[Display omitted] •Stable BSA nanoemulsions are produced by high pressure homogenization.•Linear correlation is found between Poloxamer 407 levels and size of nanoemulsions.•Presence of BSA-FA conjugate results in specific FA mediated internalization in folate receptor positive cells. Bovine serum a...
Saved in:
Published in: | Colloids and surfaces, B, Biointerfaces Vol. 135; pp. 90 - 98 |
---|---|
Main Authors: | , , , , , , , , , , , , , |
Format: | Journal Article |
Language: | English |
Published: |
Netherlands
Elsevier B.V
01-11-2015
|
Subjects: | |
Online Access: | Get full text |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Summary: | [Display omitted]
•Stable BSA nanoemulsions are produced by high pressure homogenization.•Linear correlation is found between Poloxamer 407 levels and size of nanoemulsions.•Presence of BSA-FA conjugate results in specific FA mediated internalization in folate receptor positive cells.
Bovine serum albumin (BSA) nanoemulsions were produced by high pressure homogenization with a tri-block copolymer (Poloxamer 407), which presents a central hydrophobic chain of polyoxypropylene (PPO) and two identical lateral hydrophilic chains of polyethylene glycol (PEG). We observed a linear correlation between tri-block copolymer concentration and size – the use of 5mg/mL of Poloxamer 407 yields nanoemulsions smaller than 100nm. Molecular dynamics and fluorescent tagging of the tri-block copolymer highlight their mechanistic role on the size of emulsions. This novel method enables the fabrication of highly stable albumin emulsions in the nano-size range, highly desirable for controlled drug delivery. Folic Acid (FA)-tagged protein nanoemulsions were shown to promote specific folate receptor (FR)-mediated targeting in FR positive cells. The novel strategy presented here enables the construction of size controlled, functionalized protein-based nanoemulsions with excellent characteristics for active targeting in cancer therapy. |
---|---|
Bibliography: | ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 23 |
ISSN: | 0927-7765 1873-4367 1873-4367 0927-7765 |
DOI: | 10.1016/j.colsurfb.2015.06.073 |